Most of the news in the fatty liver space lately has been about drugs that are already approved. Resmetirom got its nod in March 2024. Semaglutide got its MASH label in August 2025. And in the background, a quieter candidate has been moving on a path of its own—one that looks nothing like the others in terms of how it affects your cholesterol, your liver stiffness, and, maybe, your long-term cardiovascular risk.
That drug is pemvidutide (ALT-801), a once-weekly GLP-1/glucagon dual agonist from Altimmune. In January 2026, it received FDA Breakthrough Therapy Designation for MASH. In December 2025, its Phase 2b IMPACT trial hit every 48-week endpoint that mattered. And by the time Phase 3 starts enrolling later this year, pemvidutide will be carrying a profile that's genuinely hard to compare to anything else in the class.
This is a close look at what pemvidutide actually does, what the data says, and why the lipid numbers in particular have caught the attention of liver specialists who usually roll their eyes at "me-too" metabolic drugs.
The MASH Problem, Quickly
If you've been following this space, skip to the next section. If not, here's the situation:
MASH—metabolic dysfunction-associated steatohepatitis—is the inflammatory, scar-forming version of fatty liver disease. About 38% of adults globally have some form of metabolic liver disease (MASLD), and a meaningful subset of those progress to MASH, then fibrosis, then cirrhosis, then either liver failure or liver cancer. It is now the fastest-growing indication for liver transplant in the United States.
Until 2024, there were zero FDA-approved treatments. Now there are two:
- Resmetirom (Rezdiffra) — oral thyroid hormone receptor-beta agonist, approved March 2024. Roughly 26–30% MASH resolution rates in Phase 3.
- Semaglutide (Wegovy) — GLP-1 agonist, granted accelerated approval for MASH with F2–F3 fibrosis in August 2025.
Both work. Neither is a knockout. Both leave substantial room for something better—particularly something that addresses the liver fat, the inflammation, and the cardiometabolic risk that travels with MASH.
That "something" is what pemvidutide is trying to be.
What Pemvidutide Actually Is
Pemvidutide is a synthetic peptide that hits two receptors at once: GLP-1 (glucagon-like peptide-1) and the glucagon receptor. It's engineered with a proprietary lipid tail to extend its half-life, making it a once-weekly subcutaneous injection.
On paper, this sounds identical to survodutide, Boehringer Ingelheim's GLP-1/glucagon dual agonist that's also chasing MASH. Both drugs activate the same two receptors. But mechanism isn't the whole story—receptor balance is. Pemvidutide and survodutide have different potency ratios at each receptor, and that turns out to matter quite a bit at the level of real-world outcomes.
The Two-Receptor Logic
To understand why dual agonism makes sense for MASH specifically, you have to understand what each receptor does:
GLP-1 activation does what you'd expect from an Ozempic-class drug:
- Suppresses appetite
- Slows gastric emptying
- Improves insulin sensitivity
- Reduces caloric intake
Glucagon receptor activation in the liver does something most weight-loss drugs can't do directly:
- Stimulates fatty acid oxidation (the liver actively burns its own fat)
- Suppresses new fat synthesis (lipogenesis)
- Increases energy expenditure at rest
- Promotes mitochondrial turnover
- Increases ketogenesis
- Reduces oxidative stress
On its own, glucagon raises blood sugar—which is why you can't just give people glucagon and hope for weight loss. But when you pair it with GLP-1 activation, the GLP-1 arm counterbalances the glucose effect. You get the liver-specific fat-burning without the hyperglycemia.
That combination is what makes dual agonists especially interesting for MASH. You're not just shrinking the patient and hoping the liver follows along. You're telling the liver directly to burn its fat.
The IMPACT Phase 2b Trial: The 48-Week Data That Changed Things
The trial that matters here is IMPACT. It was announced at the end of 2025 and put pemvidutide squarely on the FDA's radar.
Design at a glance
- Participants: 212 adults with biopsy-confirmed MASH and fibrosis stage F2 or F3
- Randomization: 1:2:2 to placebo, pemvidutide 1.2 mg weekly, or pemvidutide 1.8 mg weekly
- Duration: 48 weeks of treatment
- Primary endpoint (at week 24): MASH resolution without worsening of fibrosis, or fibrosis improvement without worsening of MASH
The real story, though, is in the 48-week data. At week 48, several non-invasive markers of liver health moved dramatically.
48-Week Results: Non-Invasive Liver Tests
| Marker | Placebo | Pemvidutide 1.2 mg | Pemvidutide 1.8 mg |
|---|---|---|---|
| Liver fat reduction (MRI-PDFF) | -8.2% | -45.2% | -54.7% |
| ALT change (IU/L) | -10 | -38 | -38 |
| Enhanced Liver Fibrosis (ELF) score | +0.16 | -0.49 | -0.58 |
| Liver Stiffness Measurement (kPa) | -0.03 | -3.04 | -3.97 |
| cT1 (MRI, ms) | -21 | -124 | -140 |
Three things stand out:
- ELF score moved the wrong direction in placebo and the right direction on pemvidutide. This isn't a weight-loss artifact—MASH placebo arms frequently show small improvements just from trial participation. The fact that the placebo group got worse on ELF while pemvidutide patients improved substantially is a strong anti-fibrotic signal.
- Liver stiffness dropped by roughly 4 kPa on the 1.8 mg dose. In MASH, a shift of that magnitude is clinically meaningful and tracks with reduced fibrosis progression risk.
- The 1.8 mg dose consistently outperformed 1.2 mg without a dramatic increase in discontinuations, suggesting the drug still has headroom at higher doses.
Weight Loss at 48 Weeks
| Arm | Mean Weight Loss |
|---|---|
| Placebo | 0.2% |
| Pemvidutide 1.2 mg | 4.5% |
| Pemvidutide 1.8 mg | 7.5% |
This is where pemvidutide looks modest compared to survodutide (~18.7% at 4.8 mg) or tirzepatide (~21%+ at higher doses). But MASH dosing is not the same as obesity dosing. The 1.8 mg arm in IMPACT was picked for a liver-focused risk/benefit balance, not maximum weight loss. Altimmune's separate MOMENTUM Phase 2 obesity trial used 2.4 mg and produced 15.6% weight loss at 48 weeks—a very different number at a different dose.
Safety: The Surprise
| Outcome | Placebo | 1.2 mg | 1.8 mg |
|---|---|---|---|
| Discontinuation due to adverse event | 3.5% | 0% | 1.2% |
| Serious treatment-related AEs | None reported | None | None |
Zero dropouts on the low dose. A 1.2% dropout rate at the higher dose. No serious treatment-related adverse events. That's an unusually clean tolerability profile for a drug in this class at this stage of development—especially one where early dosing is typically plagued by nausea, vomiting, and GI-driven discontinuation.
Nausea did show up as the most common adverse event (around 33% in integrated analyses at MASH doses, rising to ~52% at the higher 2.4 mg obesity dose), but the events were predominantly mild-to-moderate and tended to resolve without intervention.
The Lipid Story: Why Cardiologists Are Paying Attention
Here's where pemvidutide genuinely stands apart from other drugs in the GLP-1 family. In the MOMENTUM Phase 2 obesity trial, pemvidutide produced lipid changes that most metabolic drugs don't touch.
48-Week Lipid Changes at 2.4 mg (MOMENTUM Obesity Trial)
| Lipid Marker | Relative Change |
|---|---|
| Total cholesterol | -15.1% |
| LDL-C | -11.2% |
| Triglycerides | -34.9% |
| Remnant cholesterol | Significantly reduced |
| Pro-inflammatory lipid mediators | Significantly reduced |
A 35% reduction in triglycerides is not a number you usually associate with a weight-loss drug. For context, semaglutide typically produces triglyceride reductions in the 15–25% range, and most of that is attributable to weight loss itself. Pemvidutide's lipid effects appear to exceed what you'd predict from weight loss alone—consistent with the direct hepatic lipogenesis suppression that the glucagon receptor drives.
Just as importantly, the lipidomic profile shifts toward an anti-atherogenic pattern: smaller LDL-C particles drop, remnant cholesterol drops, and pro-inflammatory lipid mediators decline across multiple classes. These are the kinds of changes cardiologists care about when they're thinking about long-term cardiovascular event risk, not just scale readings.
Cardiovascular Safety
The cardiovascular safety signal is equally interesting. In an integrated analysis presented at ADA 2025:
- No clinically meaningful change in heart rate (GLP-1 drugs typically increase resting heart rate by 2–5 bpm; pemvidutide doesn't appear to)
- Reductions in systolic and diastolic blood pressure
- No imbalance in cardiac adverse events versus placebo
- No arrhythmia signal
Put this together, and pemvidutide's cardiovascular footprint looks favorable in a way that could matter a lot at the population level—MASH patients are almost universally at elevated cardiovascular risk, and the leading cause of death in MASH isn't liver failure; it's cardiovascular disease.
The Lean Mass Question
Every GLP-1 conversation in 2026 comes back to the same problem: these drugs cause people to lose muscle along with fat. Estimates put lean mass loss at roughly 25–40% of total weight loss for semaglutide and tirzepatide—meaning a patient losing 20 pounds on Wegovy might be losing 5–8 pounds of lean mass in the process.
Pemvidutide's lean mass data is better than the GLP-1-only drugs but not perfect. In MOMENTUM, participants on pemvidutide had an average 21.9% lean mass loss as a share of total weight loss—meaning 78.1% of weight lost was fat. That's better than pure GLP-1 agonists (typically 60–75% fat) but not as clean as what bimagrumab combinations have shown (over 90% fat).
For MASH patients specifically—who tend to be older and at higher baseline risk of sarcopenia—this ratio matters. It's one of the reasons the MASH dosing (1.2 mg and 1.8 mg) may end up being preferred for this indication even if obesity protocols use higher doses.
How Pemvidutide Compares to the Rest of the MASH Field
There's no shortage of drugs chasing this market. Here's how the leaders stack up on what we know today:
| Drug | Class | MASH Resolution | Liver Fat Reduction | Weight Loss | FDA Status (April 2026) |
|---|---|---|---|---|---|
| Resmetirom (Rezdiffra) | THR-beta agonist | 26–30% | ~30% | Minimal | Approved (March 2024) |
| Semaglutide (Wegovy) | GLP-1 | ~37% (ESSENCE) | ~30–40% | ~10% | Approved for MASH (Aug 2025) |
| Survodutide | GLP-1/glucagon | 62% (Phase 2) | ~65% | ~18.7% | Phase 3 (Breakthrough) |
| Pemvidutide | GLP-1/glucagon | Endpoint at 24w | 54.7% (48w) | 7.5% (MASH dose) | Phase 3 starting 2026 (Breakthrough) |
| Efinopegdutide | GLP-1/glucagon | Phase 2 | Superior to sema in head-to-head | Moderate | Phase 2 |
| Tirzepatide | GLP-1/GIP | ~62% (SYNERGY-NASH) | ~55% | ~20% | Phase 3 complete, no MASH label yet |
| Retatrutide | GLP-1/GIP/glucagon | Phase 2 signals | ~85% liver fat reduction | 24–29% | Phase 3 |
A few observations:
- Pemvidutide's raw MASH resolution number isn't public yet for the Phase 2b primary endpoint (that 24-week biopsy data is the one we're still waiting on in full detail). The 48-week non-invasive test data is what's already out.
- Pemvidutide's niche is almost certainly going to be defined by its lipid profile and tolerability, not by chasing weight loss numbers. On those metrics it's in a class of its own right now.
- Survodutide is ahead on MASH resolution by raw numbers, but pemvidutide's antifibrotic signal (ELF, LSM) and cardiovascular profile may matter more for long-term outcomes.
- Retatrutide has the biggest weight loss numbers but isn't a pure MASH play. Its niche is going to be severe obesity.
The more interesting question isn't "which of these wins," it's "which combinations work together." Resmetirom + pemvidutide would combine a liver-targeted oral drug with a systemic peptide that hits different pathways. No combination trials have been announced, but the logic is there.
The Path to Phase 3
Altimmune and the FDA reached alignment on Phase 3 design at an end-of-phase 2 meeting late in 2025. Here's what's coming:
- Patient population: MASH with moderate to advanced fibrosis (F2 or F3)
- Treatment duration: 52 weeks
- Doses studied: 1.8 mg and 2.4 mg
- Enrollment: "a little under 1,000" patients
- Endpoints: biopsy-based, supporting accelerated approval pathway
- AI-assist: Use of AIM-MASH AI Assist for histological reads to reduce inter-reader variability
- Initiation: 2026
Two details worth noticing. First, the inclusion of a 2.4 mg arm in the Phase 3—a higher dose than was tested in IMPACT. This suggests Altimmune thinks there's more liver benefit to be had at the dose that maximized lipid and weight effects in MOMENTUM.
Second, the use of AI-assisted biopsy reading. MASH trials have historically been plagued by inter-reader variability on fibrosis staging—two pathologists can look at the same biopsy and disagree by an entire stage. AI assist is intended to tighten that noise, which is good for everyone: fewer false negatives and fewer false positives.
The Realistic Timeline
| Date | Milestone |
|---|---|
| December 2025 | IMPACT Phase 2b 48-week topline results |
| January 2026 | FDA Breakthrough Therapy Designation granted |
| 2026 | Phase 3 MASH trial initiation |
| 2027 (expected) | Phase 3 interim reads on non-invasive markers |
| 2028–2029 | Primary biopsy-based readout |
| 2029–2030 | Potential FDA submission (under accelerated approval pathway) |
Breakthrough Therapy Designation doesn't guarantee approval, but it does guarantee more frequent FDA contact and a cleaner regulatory path. Combined with the accelerated approval pathway that resmetirom used, pemvidutide could realistically be on the market by 2029–2030 if Phase 3 replicates Phase 2.
That's a meaningful "if." Phase 2 MASH data has, historically, been a notoriously poor predictor of Phase 3. Multiple drugs in this space—obeticholic acid, cenicriviroc, selonsertib—posted good Phase 2 data and failed in Phase 3. The biggest reason is usually the biopsy endpoint variability mentioned above. Non-invasive marker improvements like pemvidutide's ELF and LSM reductions are a more robust anti-fibrotic signal than most Phase 2 MASH drugs have shown, but they're still not a guarantee.
What This Means Practically
Pemvidutide is not available outside of clinical trials. It is not sold legally in the US, it is not being compounded by any reputable pharmacy, and anyone offering it online is either selling research chemicals of unverified purity or running an outright scam. There is no circumstance in which buying pemvidutide from a gray-market supplier makes sense in 2026.
That said, for anyone trying to understand where the metabolic drug field is going, pemvidutide is worth tracking for three reasons:
- It's the clearest example yet that GLP-1/glucagon dual agonism has a different risk/benefit profile than GLP-1 monotherapy, particularly for cardiometabolic markers like triglycerides and remnant cholesterol.
- The antifibrotic signal in IMPACT is one of the strongest we've seen at this stage of development. Other drugs have beaten placebo on fibrosis improvement rates, but few have moved ELF scores this far this consistently.
- It fits into an emerging treatment logic where MASH is treated not as a single-drug problem but as a multi-mechanism problem—combining an oral liver-targeted drug like resmetirom with a systemic metabolic drug like pemvidutide could become standard of care by the end of the decade.
The Bottom Line
Pemvidutide is a GLP-1/glucagon dual agonist that just cleared a major bar: Phase 2b success on the endpoints that mattered, FDA Breakthrough Therapy Designation, Phase 3 initiation in 2026. Its weight loss numbers are modest by 2026 standards. Its liver-specific numbers are strong. Its lipid profile is, by some measures, genuinely best-in-class.
It is not a done deal. Phase 3 MASH trials are unforgiving. The Phase 2 biopsy endpoint at 24 weeks, in detail, will matter enormously. And the drug will need to prove durability beyond 48 weeks.
But right now, in the crowded MASH race, pemvidutide has earned its seat at the table. It's not trying to be the biggest weight-loss number; it's trying to be the best liver and lipid drug in the class. If Phase 3 holds, that's a position worth having—because the MASH patient population isn't dying from a BMI chart. They're dying from cardiovascular disease, from fibrosis progression, and from the downstream complications of a liver that's been burning for decades.
Fixing those patients well is going to take multiple drugs, multiple mechanisms, and a lot more data. Pemvidutide may turn out to be a central piece of that answer.
This article is for informational and educational purposes only. Pemvidutide is an investigational drug and is not approved by the FDA for any indication. It is not available for purchase outside of authorized clinical trials. Do not attempt to obtain or use pemvidutide through gray-market or compounding-pharmacy channels. Consult a qualified healthcare provider before making any decisions about MASH, obesity, or metabolic disease treatment.